<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00186537</url>
  </required_header>
  <id_info>
    <org_study_id>79301</org_study_id>
    <secondary_id>SPO 28829</secondary_id>
    <nct_id>NCT00186537</nct_id>
  </id_info>
  <brief_title>Comparing Tricor, Avandia, or Weight Loss to Lower Cardiovascular Risk Factors in People With High Triglycerides.</brief_title>
  <official_title>Comparison Fenofibrate, Rosiglitazone, or Weight Loss to Decrease Cardiovascular Risk in Insulin Resistant Dyslipidemic Individuals.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Approximately 1/4 of the US population has insulin resistance and the associated risk factors
      such as elevated lipid levels -triglycerides (type of fat from what we eat and what the liver
      produces and low HDL cholesterol which is the good cholesterol helping to protect against
      heart disease. Currently one known treatment for this a medication called fenofibrate,
      another medication that can improve insulin resistance is rosiglitazone, a third treatment
      known to improve insulin resistance an decrease triglycerides is weight loss. In this study
      insulin resistant individuals with elevated triglycerides and or a ratio of triglycerides to
      HDL cholesterol of 3:1 or greater will be randomized (selected by chance) to receive one of
      these treatments and results of insulin sensitivity and cardiac risk profiles will be
      compared at the end of the study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It has been estimated that approximately Â¼ of the US population has the Insulin Resistant
      Syndrome (IRS). The notion that insulin resistance and compensatory hyperinsulinemia lead to
      a cluster of abnormalities that increase CVD risk was first introduced in 1988, and central
      to the changes identified was a dyslipidemia characterized by a high plasma triglyceride (TG)
      and low high-density lipoprotein cholesterol (HDL-C) concentration. The atherogenic
      lipoprotein pattern associated with the IRS has grown to include enhanced postprandial
      lipemia and smaller and denser low-density lipoprotein (LDL) particles. In addition to being
      associated with insulin resistance and compensatory hyperinsulinemia, these changes in
      lipoprotein metabolism have been identified as increasing CVD risk. The power of the
      dyslipidemia associated with the IRS is reinforced by reports that the plasma TG/HDL-C
      concentration ratio is as powerful a predictor of CVD, if not more so, than the more
      conventional total plasma cholesterol/LDL-C concentration ratio, and evidence from the
      Copenhagen Male Study of the interaction between the plasma TG and HDL-C concentrations,
      &quot;conventional&quot; CVD risk factors, and CVD events. Specifically, these latter investigators
      were able to show in a prospective study (11) that CVD events were substantially attenuated
      in: 1) smokers; 2) patients with high blood pressure; 3) individuals with a high LDL-C
      concentration; and 4) subjects who were sedentary; as long as they were in the lowest 1/3rd
      of the population with the lowest TG/HDL-C concentration ratio and presumably insulin
      sensitive. Conversely, if they were in the tertile with the highest plasma TG/HDL-C
      concentration ratio, and presumably insulin resistant, they had a significant increase in CVD
      events in the absence of the four conventional CVD risk factors evaluated.

      An obvious alternative therapeutic approach to decreasing CVD risk in patients with the IRS
      would be to administer a thiazolidinedione (TZD) compound in an effort to directly treat the
      basic defect of the syndrome. However, based upon our own results with rosiglitazone (ROSI)
      in several different patient populations, improvements in insulin sensitivity were not
      associated with a significant improvement in dyslipidemia. For example, in a recent study
      (unpublished) of ROSI-treated patients with type 2 diabetes, neither plasma TG (358 to 347
      mg/dL) nor HDL-C (40 to 42 mg/dL) concentrations improved, and both total (215 to 239 mg/dL
      and LDL-C (118-142mg/dL) concentrations actually increased. Since the patients in this study
      became more insulin sensitive with treatment, and had lower daylong plasma glucose, insulin,
      and free fatty acid concentrations, the reason for the lack of a beneficial effect of ROSI on
      lipoprotein metabolism is not clear. On the other hand, given evidence of the importance of
      dyslipidemia in increasing CVD risk in insulin resistant individuals, it seems reasonable to
      question the notion that TZD compounds provide the most beneficial approach to decreasing CVD
      risk in the dyslipidemic patient with the IRS.

      With this background in mind, we propose to initiate a study in which insulin resistant
      individuals with the dyslipidemia characteristic of the IRS will be randomized to treatment
      with fenofibrate,ROSI, or weight loss and the effect of these three treatments on CVD risk
      factors compared. It is postulated that although insulin resistance will improve to a greater
      degree with ROSI treatment, the atherogenic lipoprotein profile known to link IRS and CVD
      will only significantly improve following treatment with fenofibrate and effects of weight
      loss can effect both of these.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2003</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pre- and Post-Intervention Triglyceride Levels</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>Compare the change in mean triglyceride levels between groups after the interventions</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pre- and Post-Intervention LDL Cholesterol Levels</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>Compare the change in mean LDL Cholesterol levels between groups after the interventions</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pre- and Post-Intervention HDL Cholesterol Levels</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>Compare the change in mean HDL Cholesterol levels between groups after the interventions</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Insulin Resistance</condition>
  <condition>Hypertriglyceridemia</condition>
  <arm_group>
    <arm_group_label>fenofibrate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>160 mg daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rosiglitazone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>4 mg/daily 4 weeks followed by 4 mg 2 x daily for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>calorie restricted diet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>calorie restricted to achieve 0.5 kg weight loss/week x 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosiglitazone</intervention_name>
    <arm_group_label>rosiglitazone</arm_group_label>
    <other_name>avandia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fenofibrate</intervention_name>
    <arm_group_label>fenofibrate</arm_group_label>
    <other_name>tricor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Weight Loss</intervention_name>
    <arm_group_label>calorie restricted diet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Insulin Resistant Triglyceride 150 mg/dL or greater or triglyceride HDL-C ratio 3 or
        greater BMI 25-35

        Exclusion Criteria:

        Diabetes Mellitus History of gall stones History of CHF History of CAD Severe
        anemia,kidney, or liver disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerald M Reaven, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988 Dec;37(12):1595-607. Review.</citation>
    <PMID>3056758</PMID>
  </reference>
  <reference>
    <citation>Laws A, Reaven GM. Evidence for an independent relationship between insulin resistance and fasting plasma HDL-cholesterol, triglyceride and insulin concentrations. J Intern Med. 1992 Jan;231(1):25-30.</citation>
    <PMID>1732395</PMID>
  </reference>
  <reference>
    <citation>Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002 Jan 16;287(3):356-9.</citation>
    <PMID>11790215</PMID>
  </reference>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 14, 2005</study_first_submitted>
  <study_first_submitted_qc>September 14, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2005</study_first_posted>
  <results_first_submitted>April 1, 2016</results_first_submitted>
  <results_first_submitted_qc>April 1, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 5, 2016</results_first_posted>
  <last_update_submitted>November 21, 2016</last_update_submitted>
  <last_update_submitted_qc>November 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Gerald M Reaven</investigator_full_name>
    <investigator_title>Professor Emeritus</investigator_title>
  </responsible_party>
  <keyword>Insulin resistance</keyword>
  <keyword>Insulin resistance syndrome</keyword>
  <keyword>dyslipidemia</keyword>
  <keyword>atherogenic dyslipidemia</keyword>
  <keyword>triglyceride/HDL-C ratio</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Weight Loss</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Hypertriglyceridemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosiglitazone</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Fenofibrate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Fenofibrate</title>
          <description>160 mg daily for 12 weeks
Fenofibrate</description>
        </group>
        <group group_id="P2">
          <title>Rosiglitazone</title>
          <description>4 mg/daily 4 weeks followed by 4 mg 2 x daily for 8 weeks
Rosiglitazone</description>
        </group>
        <group group_id="P3">
          <title>Calorie Restricted Diet</title>
          <description>calorie restricted to achieve 0.5 kg weight loss/week x 12 weeks
Weight Loss</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>ALT &gt; 1.5 x ULN</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline analysis was done on those who completed the study</population>
      <group_list>
        <group group_id="B1">
          <title>Fenofibrate</title>
          <description>160 mg daily for 12 weeks
Fenofibrate</description>
        </group>
        <group group_id="B2">
          <title>Rosiglitazone</title>
          <description>4 mg/daily 4 weeks followed by 4 mg 2 x daily for 8 weeks
Rosiglitazone</description>
        </group>
        <group group_id="B3">
          <title>Calorie Restricted Diet</title>
          <description>calorie restricted to achieve 0.5 kg weight loss/week x 12 weeks
Weight Loss</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="13"/>
            <count group_id="B4" value="37"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55" spread="7"/>
                    <measurement group_id="B2" value="52" spread="6"/>
                    <measurement group_id="B3" value="53" spread="7"/>
                    <measurement group_id="B4" value="53" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pre- and Post-Intervention Triglyceride Levels</title>
        <description>Compare the change in mean triglyceride levels between groups after the interventions</description>
        <time_frame>Baseline, 12 weeks</time_frame>
        <population>Triglycerides</population>
        <group_list>
          <group group_id="O1">
            <title>Fenofibrate</title>
            <description>160 mg daily for 12 weeks
Fenofibrate</description>
          </group>
          <group group_id="O2">
            <title>Rosiglitazone</title>
            <description>4 mg/daily 4 weeks followed by 4 mg 2 x daily for 8 weeks
Rosiglitazone</description>
          </group>
          <group group_id="O3">
            <title>Calorie Restricted Diet</title>
            <description>calorie restricted to achieve 0.5 kg weight loss/week x 12 weeks
Weight Loss</description>
          </group>
        </group_list>
        <measure>
          <title>Pre- and Post-Intervention Triglyceride Levels</title>
          <description>Compare the change in mean triglyceride levels between groups after the interventions</description>
          <population>Triglycerides</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>pre treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="231" spread="117"/>
                    <measurement group_id="O2" value="209" spread="67"/>
                    <measurement group_id="O3" value="201" spread="121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>post treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="140" spread="47"/>
                    <measurement group_id="O2" value="232" spread="72"/>
                    <measurement group_id="O3" value="143" spread="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pre- and Post-Intervention LDL Cholesterol Levels</title>
        <description>Compare the change in mean LDL Cholesterol levels between groups after the interventions</description>
        <time_frame>Baseline, 12 weeks</time_frame>
        <population>LDL cholesterol</population>
        <group_list>
          <group group_id="O1">
            <title>Fenofibrate</title>
            <description>160 mg daily for 12 weeks
Fenofibrate</description>
          </group>
          <group group_id="O2">
            <title>Rosiglitazone</title>
            <description>4 mg/daily 4 weeks followed by 4 mg 2 x daily for 8 weeks
Rosiglitazone</description>
          </group>
          <group group_id="O3">
            <title>Calorie Restricted Diet</title>
            <description>calorie restricted to achieve 0.5 kg weight loss/week x 12 weeks
Weight Loss</description>
          </group>
        </group_list>
        <measure>
          <title>Pre- and Post-Intervention LDL Cholesterol Levels</title>
          <description>Compare the change in mean LDL Cholesterol levels between groups after the interventions</description>
          <population>LDL cholesterol</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>pre treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114" spread="34"/>
                    <measurement group_id="O2" value="119" spread="41"/>
                    <measurement group_id="O3" value="144" spread="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>post treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111" spread="22"/>
                    <measurement group_id="O2" value="129" spread="37"/>
                    <measurement group_id="O3" value="128" spread="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pre- and Post-Intervention HDL Cholesterol Levels</title>
        <description>Compare the change in mean HDL Cholesterol levels between groups after the interventions</description>
        <time_frame>Baseline, 12 weeks</time_frame>
        <population>HDL Cholesterol</population>
        <group_list>
          <group group_id="O1">
            <title>Fenofibrate</title>
            <description>160 mg daily for 12 weeks
Fenofibrate</description>
          </group>
          <group group_id="O2">
            <title>Rosiglitazone</title>
            <description>4 mg/daily 4 weeks followed by 4 mg 2 x daily for 8 weeks
Rosiglitazone</description>
          </group>
          <group group_id="O3">
            <title>Calorie Restricted Diet</title>
            <description>calorie restricted to achieve 0.5 kg weight loss/week x 12 weeks
Weight Loss</description>
          </group>
        </group_list>
        <measure>
          <title>Pre- and Post-Intervention HDL Cholesterol Levels</title>
          <description>Compare the change in mean HDL Cholesterol levels between groups after the interventions</description>
          <population>HDL Cholesterol</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>pre treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35" spread="7"/>
                    <measurement group_id="O2" value="40" spread="11"/>
                    <measurement group_id="O3" value="38" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36" spread="8"/>
                    <measurement group_id="O2" value="42" spread="13"/>
                    <measurement group_id="O3" value="38" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Fenofibrate</title>
          <description>160 mg daily for 12 weeks
Fenofibrate</description>
        </group>
        <group group_id="E2">
          <title>Rosiglitazone</title>
          <description>4 mg/daily 4 weeks followed by 4 mg 2 x daily for 8 weeks
Rosiglitazone</description>
        </group>
        <group group_id="E3">
          <title>Calorie Restricted Diet</title>
          <description>calorie restricted to achieve 0.5 kg weight loss/week x 12 weeks
Weight Loss</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>alanine aminotramsferase ( ALT) elevation greater than 1.5 times normal of upper limit</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Gerald Reaven</name_or_title>
      <organization>Stanford University</organization>
      <phone>650-724-3416</phone>
      <email>greaven@stanford.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

